✦ LIBER ✦

Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma

✍ Scribed by Klaus Buchali; Hans-Jacob Correns; Michael Schuerer; Dietmar Schnorr; Hildegard Lips; Karin Sydow

Publisher: Springer
Year: 1988
Tongue: English
Weight: 249 KB
Volume: 14-14
Category: Article
ISSN: 0340-6997
DOI: 10.1007/bf00254382

No coin nor oath required. For personal study only.

✦ Synopsis

Forty-nine patients were treated with either 3 x 75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of 89Sr therapy on life expectation.

📜 SIMILAR VOLUMES

89Strontium therapy of bone metastases o

89Strontium therapy of bone metastases of carcinoma of the prostatic gland

✍ Hans-Jacob Correns; Moritz Mebel; Klaus Buchali; Dietmar Schnorr; Christian Seid 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 179 KB

Following a firm diagnostic and therapeutic schedule for patients with prostatic carcinoma. 89Strontium therapy was introduced for multiple metastases. Positive skeletal scintigraphy with 99mTc-EHDP induced check for affinity to Sr using 85Sr scintigraphy. Of 80 patients, multiple metastases were fo

Sr-89 therapy: Strontium kinetics in dis

Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate

✍ G. M. Blake; M. A. Zivanovic; A. J. McEwan; D. M. Ackery 📂 Article 📅 1986 🏛 Springer 🌐 English ⚖ 824 KB

Strontium kinetics were investigated in a group of 14 patients receiving 89Sr palliation for metastatic bone disease secondary to prostatic carcinoma. Using 85Sr as a tracer, total body strontium retention R(t) was monitored for a 3 month period following 89Sr administration, and at 90 days was foun

The effect of repeated strontium-89 chlo

The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases

✍ Jan Kasalický; Věra Krajská 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 72 KB

A Phase I/II study of strontium-89 combi

A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases

✍ Lance C. Pagliaro; Ebrahim S. Delpassand; Dallas Williams; Randall E. Millikan; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract ## BACKGROUND The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontium‐89 to patients with androgen independent prostate carcinoma. ## METHODS Patients with androgen‐independent pr

Palliation of pain from bone metastases

Palliation of pain from bone metastases in prostate cancer: Strontium-89 or external beam radiotherapy? results of a prospective randomised trial

✍ D.P. Dearnaleyl; J.J. Bolger; D. Kirk; V. Lewington; P.M. Quilty; N.S. Reed; J.M 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 201 KB

Candicidin treatment of prostatism: A pr

Candicidin treatment of prostatism: A prospective double-blind placebo-controlled study

✍ Jensen, K. M.-E. ;Madsen, P. O. 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 385 KB

The polyene macrolide candicidin was investigated in the treatment of benign prostatic hyperplasia (BPH). Forty-one unselected patients with BPH and prostatism were admitted to a prospective, double-blind placebo-controlled clinical trial. Patients treated with 270 mg candicidin daily for 6 months h